
|Videos|September 6, 2017
Dr. Rosenberg Discusses the Importance of Clinical Trials in Bladder Cancer
Author(s)Jonathan E. Rosenberg, MD
Jonathan E. Rosenberg, MD, medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the importance of referring patients to clinical trials in bladder cancer.
Advertisement
Jonathan E. Rosenberg, MD, medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the importance of referring patients to clinical trials in bladder cancer.
There is a long history of failed adjuvant clinical trials in bladder cancer due to poor accrual, says Rosenberg. He says that is important for treating physicians to recommend patients for these trials in order to test novel adjuvant therapies.
Adjuvant immunotherapy trials are showing greater success in accrual though, Rosenberg adds.
Clinicians referring a patient to MSK can do so by visiting msk.org/refer, emailing [email protected], or by calling 833-315-2722.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Zenocutuzumab for NRG1 Fusion+ Cholangiocarcinoma
2
Poll Results Highlight Breast Cancer Abstracts of Interest at ASCO 2026
3
Capivasertib/Fulvestrant Yields Numerical OS Advantage in PIK3CA/AKT1/PTEN–Altered Breast Cancer
4
OncLive Polls Reveal Picks for Top Lung Cancer Abstracts at ASCO 2026
5


















































